Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas A Stewart

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Expert Opinion on Biological Therapy|January 31, 2012
Obinutuzumab for the treatment of lymphoproliferative disordersCarolyn Owen, Douglas A Stewart
Expert Opinion on Biological Therapy|May 24, 2017
Targeting non-Hodgkin lymphoma with blinatumomabSheilagh Sanders, Douglas A Stewart
Therapeutic Advances in Hematology|August 20, 2015
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspectiveCarolyn J Owen, Douglas A Stewart
Expert Opinion on Biological Therapy|May 27, 2014
Obinutuzumab for B-cell malignanciesCarolyn J Owen, Douglas A Stewart
Leukemia & Lymphoma|June 30, 2009
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantationDouglas A Stewart, Nizar Bahlis, Adnan Mansoor
Expert Opinion on Pharmacotherapy|March 12, 2021
Novel synthetic drugs for the treatment of non-Hodgkin lymphomaFarheen Manji, Robert Puckrin, Douglas A Stewart
Transplantation and Cellular Therapy|February 5, 2022
Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based AnalysisRobert Puckrin, Douglas A Stewart, Mona Shafey
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2009
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myelomaDouglas A Stewart, Clayton Smith, Ron MacFarland, et al.
Leukemia & Lymphoma|April 23, 2022
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplantRobert Puckrin, Neil Chua, Mona Shafey, et al.
Leukemia & Lymphoma|August 3, 2002
ALK-positive anaplastic large T-cell lymphoma preceded by Epstein-Barr virus infection complicated by development of an aorto-esophageal fistulaSean M Bagshaw, Trudy Crabtree, Francis Green, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Expert Opinion on Biological Therapy|January 31, 2012
Obinutuzumab for the treatment of lymphoproliferative disordersCarolyn Owen, Douglas A Stewart
Expert Opinion on Biological Therapy|May 24, 2017
Targeting non-Hodgkin lymphoma with blinatumomabSheilagh Sanders, Douglas A Stewart
Therapeutic Advances in Hematology|August 20, 2015
Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspectiveCarolyn J Owen, Douglas A Stewart
Expert Opinion on Biological Therapy|May 27, 2014
Obinutuzumab for B-cell malignanciesCarolyn J Owen, Douglas A Stewart
Leukemia & Lymphoma|June 30, 2009
pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantationDouglas A Stewart, Nizar Bahlis, Adnan Mansoor
Expert Opinion on Pharmacotherapy|March 12, 2021
Novel synthetic drugs for the treatment of non-Hodgkin lymphomaFarheen Manji, Robert Puckrin, Douglas A Stewart
Transplantation and Cellular Therapy|February 5, 2022
Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based AnalysisRobert Puckrin, Douglas A Stewart, Mona Shafey
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 13, 2009
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myelomaDouglas A Stewart, Clayton Smith, Ron MacFarland, et al.
Leukemia & Lymphoma|April 23, 2022
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplantRobert Puckrin, Neil Chua, Mona Shafey, et al.
Leukemia & Lymphoma|August 3, 2002
ALK-positive anaplastic large T-cell lymphoma preceded by Epstein-Barr virus infection complicated by development of an aorto-esophageal fistulaSean M Bagshaw, Trudy Crabtree, Francis Green, et al.
Pageof 7